If you are considering psychedelic-assisted treatment in Italy — for yourself or for someone close to you — the honest picture in July 2026 is one strong public route, one very small private one, and a research landscape that does not yet include classic psychedelics. Esketamine through the hospital system is real and reimbursed; everything involving psilocybin or MDMA is not available outside research, and right now there is no Italian trial to join for either. This guide covers who qualifies, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.
TL;DR Spravato (esketamine) has been reimbursed as a hospital medicine (Classe H) since May 2022 — AIFA Determina 334/2022 — for adults with treatment-resistant depression after at least two failed antidepressants in the current moderate-to-severe episode. Treatment runs through regionally authorized hospital psychiatric centers, with each patient entered in an AIFA monitoring registry. The newer psychiatric-emergency indication was placed in Classe C in 2024 and is not reimbursed. Private ketamine is legal off-label but the market is minimal. Psilocybin and MDMA are strictly controlled, and no Italian trial for either is recruiting as of July 2026 — the recruiting studies are ketamine and esketamine trials in Milan and at four university sites.
At a glance
| Route | Substance | Status in Italy | Who qualifies | Cost |
|---|---|---|---|---|
| Reimbursed esketamine | Esketamine (Spravato) | Classe H since May 2022; running | Adults with treatment-resistant depression: at least two failed antidepressants in the current moderate-to-severe episode, alongside an SSRI or SNRI | Covered by the SSN as a hospital medicine |
| Private ketamine | Ketamine (off-label) | Legal under physician responsibility; very small market | Clinic screening, typically treatment-resistant depression | Self-pay; not reimbursed by the SSN for psychiatric use |
| Psilocybin therapy | Psilocybin | Strictly controlled (DPR 309/1990); research only, no trial recruiting | — | — |
| MDMA therapy | MDMA | Strictly controlled (DPR 309/1990); research only, no trial recruiting | — | — |
| Clinical trials | Ketamine, esketamine | Two recruiting studies | Study-specific criteria | Free |
Esketamine (Spravato): the reimbursed hospital route
Since May 2022, esketamine nasal spray is reimbursed by the national health service as a Classe H medicine — the hospital class — under AIFA Determina n. 334/2022, published in the Gazzetta Ufficiale on 18 May 2022. The reimbursed indication is treatment-resistant major depression: adults whose current moderate-to-severe episode has not responded to at least two different antidepressants taken at adequate dose and duration, treated with esketamine in combination with an SSRI or SNRI.
Classe H shapes everything practical about this route. The medicine is not something you collect at a pharmacy: it is dispensed, administered and monitored inside accredited hospital psychiatric units, and only at centers their region has authorized. After the national decision, Italian regions issued implementing decrees naming which hospitals may prescribe and administer Spravato — Veneto's decree is a published example — so which center you attend depends on where you live. Prescribers also enter every patient into the AIFA monitoring registry, the web-based system Italy uses for closely watched medicines: your eligibility is documented there before treatment starts and your course is tracked in it.
How to start. The route runs through a psychiatrist — in a public mental-health service (CSM) or hospital clinic — who refers you to an authorized center. The practical currency is a written treatment history: every antidepressant tried in the current episode, with substance, dose, duration and outcome. The registry entry is built from exactly this record, so assembling it before the first appointment does more than anything else to shorten the process.
Cost. For patients who meet the criteria, the medicine and its administration are covered as hospital care. One nuance is worth knowing: esketamine's separate psychiatric-emergency indication — the rapid short-term reduction of depressive symptoms in an acute situation — was classified by AIFA in Classe C in 2024, which means it is not reimbursed by the SSN. In practice, the treatment-resistant depression pathway is the funded one; if a hospital uses esketamine in an emergency context, that use sits outside national reimbursement. Compare how Italy's arrangement fits the rest of the continent in our Europe-wide reimbursement map.
Private ketamine: legal off-label, but a very small market
Racemic ketamine is an authorized medicine in Italy — an anaesthetic — and physicians may use it off-label for depression under their own responsibility, within Italy's off-label rules. What Italy does not have is a meaningful private ketamine-clinic market: unlike Germany or the UK, only a handful of providers advertise this care at all.
The main listed provider is Florence's Istituto di Neuroscienze, the clinical neuroscience center founded by Prof. Stefano Pallanti, which offers ketamine infusions and intranasal esketamine for treatment-resistant depression alongside neuromodulation (TMS and related techniques), pharmacotherapy and psychotherapy. The institute does not publish an itemized fee schedule, so ask for a written cost breakdown — per session and per course — before starting. Off-label psychiatric ketamine is not reimbursed by the SSN, so this route is self-pay from the first appointment.
The standard cautions apply with extra force in a market this small: confirm the treating physician's registration, expect a full psychiatric and medical screening before any treatment decision, and treat any provider who skips that assessment as a warning sign. Our directory for Italy lists what we have verified.
Psilocybin and MDMA: strictly controlled, research only
Psilocybin, MDMA and the other classic psychedelics are controlled under Italy's consolidated narcotics law, DPR 309/1990, in the most restrictive tables — the Ministry of Health has kept the tables current, including a 2022 decree that explicitly added ayahuasca and its component alkaloids. There is no medical-access, compassionate-use or reimbursement route for either substance, and anyone offering psilocybin or MDMA therapy commercially in Italy is operating illegally.
The research picture is equally plain: as of July 2026, no psilocybin or MDMA trial with an Italian site is listed as recruiting on ClinicalTrials.gov. Italy has an increasingly visible professional ecosystem — the Italian Society for Psychedelic Medicine (SIMEPSI) and advocacy groups such as the Luca Coscioni Association argue for research access — but that has not yet translated into recruiting studies or a legislative pathway. If psilocybin- or MDMA-assisted therapy matters to you, the realistic options are watching the registries for new Italian studies or considering trial sites elsewhere in Europe — our trials guide explains how to search and what participation involves.
Clinical trials in Italy
The trials that do exist are ketamine and esketamine studies, and two are recruiting. Blossom currently tracks three trials connected to Italy, two of them active (country report):
- Ketamina (NCT07088380) at IRCCS Ospedale San Raffaele Turro in Milan: a randomized, double-blind Phase 3 study testing whether intravenous ketamine given during electroconvulsive therapy sessions improves outcomes in hospitalized adults with treatment-resistant depression.
- INTENSIFY MDD (NCT05973851): a European Phase 3 study of early-intensified treatment — a second-line antidepressant plus esketamine or ketamine — versus treatment as usual after a first failed antidepressant, with Italian sites in Brescia, Cagliari, Naples and Turin.
Participation is free and legal, but screening is strict and enrolment is never guaranteed. See the trials guide for how phases, placebo and consent work, browse trial sites in Italy, and search ClinicalTrials.gov for current listings.
What to expect in treatment
Whichever route you take, the shape of care is similar. It begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled.
On a Spravato day at an authorized center you self-administer the nasal spray under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; a detached, dreamlike sensation and a temporary rise in blood pressure are expected effects that settle as the drug clears. You must not drive for the rest of the day, so arrange a ride home. Sessions are more frequent in the induction weeks and then taper based on measured response, always alongside your continuing oral antidepressant, with everything recorded in the AIFA registry.
A private ketamine session is usually built around an infusion given intravenously over about 40–60 minutes, with the same vital-sign monitoring and a recovery period afterwards. In Italy the medicine typically comes embedded in a broader treatment plan — pharmacotherapy, sometimes neuromodulation, ideally psychotherapy — and it is fair to ask any provider exactly how preparation and follow-up are structured, since off-label care has no single national protocol.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation, nausea, dizziness and a short-lived rise in blood pressure and heart rate. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
- A personal or family history of psychosis or bipolar disorder, which prescribing criteria and trial protocols screen for carefully.
- Severe liver disease or other serious somatic illness.
- Pregnancy or breastfeeding.
- Substance-use concerns, particularly patterns of compulsive use; centers also assess acute suicide risk before and during treatment.
A responsible provider screens for all of these before the first session. If a clinic is willing to treat you without that assessment, treat it as a warning sign. To see who is listed near you, browse providers in Italy.
Frequently asked questions
Is Spravato free for patients in Italy?
If you meet the treatment-resistant depression criteria and are treated at a regionally authorized center, the medicine is covered by the SSN as a Classe H hospital medicine — you do not buy it at a pharmacy, and administration happens within hospital care. The gatekeepers are the criteria, the regional list of centers and the AIFA registry, not a payment.
What is the AIFA monitoring registry and does it affect me?
It is the national web-based system AIFA uses to track closely watched medicines. Your prescriber documents your eligibility in it before treatment and records your course in it afterwards. For you it mainly means the documentation of your failed treatments has to be solid — the registry entry is built from it.
Why is the psychiatric-emergency use of esketamine not covered?
AIFA classified that separate indication in Classe C in 2024, which excludes it from SSN reimbursement. The funded pathway is the treatment-resistant depression indication under Determina 334/2022. If cost matters — and it usually does — make sure your case is assessed under the TRD pathway.
Can I get ketamine infusions privately in Italy?
Legally yes: off-label use under physician responsibility is permitted. Practically, the market is very small — Florence's Istituto di Neuroscienze is the main listed provider — and treatment is self-pay, since the SSN does not reimburse psychiatric ketamine. Ask for a written cost plan and a full screening before committing.
Is psilocybin or MDMA therapy available anywhere in Italy?
No. Both are strictly controlled under DPR 309/1990, there is no medical-access route, and as of July 2026 no Italian psilocybin or MDMA trial is recruiting. Anyone selling such therapy in Italy today is acting illegally. The realistic options are registries and trial sites elsewhere in Europe.
Does it matter which region I live in?
Yes, in one specific way: regions authorize the hospital centers that may deliver Spravato, so availability and waiting differ by region. Your psychiatrist will know the authorized center for your area; being treated outside your region is sometimes possible within the SSN, but ask the receiving center first.
Sources
- Gazzetta Ufficiale — AIFA Determina n. 334/2022 (Spravato, Classe H)
- AIFA — monitoring registries for supervised medicines
- Regione Veneto — implementing decree identifying authorized Spravato centers
- Blossom: Italy country report
- Blossom: Medical access in Italy
- Psychedelic Alpha: Worldwide psychedelic laws tracker
- Psychedelic Alpha: Beyond Clinical Trials — psychedelic-assisted therapy in Europe's real world (01/2026)
- EMA: Spravato (esketamine) EPAR
- ClinicalTrials.gov: NCT07088380 — ketamine augmentation of ECT in treatment-resistant depression (Milan)
- ClinicalTrials.gov: NCT05973851 — INTENSIFY MDD (Italian sites: Brescia, Cagliari, Naples, Turin)
- Ministero della Salute — decree of 23 February 2022 updating the DPR 309/1990 tables (G.U. 14 March 2022)
- Istituto di Neuroscienze, Florence — treatments and programs
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations, regional center lists and reimbursement rules change; always verify current requirements with AIFA, your region, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.